Table 3. Growth under IGF-1 therapy at different stages in primary IGF-1 deficiency.

Studies, first year	N	Age (years)	Height (SDS) at start of treatment	Dose rhIGF-1 (µg/kg body weight)	Manufacturer of rhIGF-1	Growth rate in first year (cm/y)	Height (SDS) at end of treatment
Klinger, Laron (14)*1	9	7.4	–5.7	150–200; 1×	Fujisawa, Japan	8.2	–
Backeljauw et al. (18)*1	8	6.6	–5.6	80–120; 2×	Genentech, USA	9.3	–
Ranke et al. (16)*1	26	8.2	–6.5	40–120; 2×	Pharmacia, Sweden	8.5	–
Guevara et al. (24)*1	22	9.1	–8.4	80–120; 2×	Genentech, USA	8.9	–
Chernausek et al. (20)*1	59	7.8	–6.5	40–120; 2×	Genentech, USA	8.0	–
Long term studies						Duration of treatment
Ranke et al. (17)	17	9.1	–6.5	40–120; 2×	Pharmacia, Sweden	4 years	–4.8*3
Chernausek et al. (20)	6	9.9	–7.3	40–120; 2×	Genentech, USA	7 years (adult)	–4.8*4

^*1 not randomized, not controlled; ^*2 dose randomized; ^*3 gain of 1.7 standard deviation scores (SDS) = approx. 10 cm, ^*4 gain of 2.5 SDS = approx. 17 cm. Relevant studies were listed; the few individual case reports were not included.